Share-based Payment Arrangement, Expense of Tourmaline Bio, Inc. from 31 Mar 2020 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tourmaline Bio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Jun 2025.
  • Tourmaline Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $2,466,000, a 38% increase year-over-year.
  • Tourmaline Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $8,155,000, a 0.22% increase year-over-year.
  • Tourmaline Bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,593,000, a 14% increase from 2023.
  • Tourmaline Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,769,000, a 2858% increase from 2022.
  • Tourmaline Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $195,000, a 95% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Tourmaline Bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $8,155,000 $2,466,000 +$677,000 +38% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $7,478,000 $2,273,000 +$885,000 +64% 01 Jan 2025 31 Mar 2025 10-Q 02 May 2025 2025 Q1
Q4 2024 $6,593,000 $1,735,000 -$325,000 -16% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $6,918,000 $1,681,000 -$1,219,000 -42% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $8,137,000 $1,789,000 +$1,373,000 +330% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $6,764,000 $1,388,000 +$995,000 +253% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2025 2025 Q1
Q4 2023 $5,769,000 $2,060,000 +$9,949,000 20 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $2,900,000 -$141,000 -4.6% 19 Oct 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $4,180,000 $706,000 -$2,335,000 -77% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $4,039,000 $416,000 -$2,430,000 -85% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,609,000 $393,000 -$1,804,000 -82% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $195,000 $7,889,000 -$8,882,000 -894% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $9,077,000 $3,041,000 +$1,987,000 +189% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $7,090,000 $2,846,000 +$1,950,000 +218% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $5,140,000 $2,197,000 +$1,362,000 +163% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $3,778,000 $993,000 +$401,000 +68% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $3,377,000 $1,054,000 +$867,000 +464% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $2,510,000 $896,000 +$776,000 +647% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $1,734,000 $835,000 +$712,000 +579% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $1,022,000 $592,000 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $187,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $120,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $123,000 01 Jan 2020 31 Mar 2020 10-Q 14 Jun 2021 2021 Q1

Tourmaline Bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,593,000 +$824,000 +14% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $5,769,000 +$5,574,000 +2858% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $195,000 -$3,583,000 -95% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $3,778,000 +$2,756,000 +270% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $1,022,000 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.